Richards et al reported that non-EGFR ERBB family members (ERBB2, ERBB3 and ERBB4) contributed to NB growth and survival, and that pan-ERBB inhibition, rather than an EGFR specific inhibitor, represents a potential therapeutic target (21). The gene discussed is ERBB3; the disease is neuroblastoma.